Multiplex PCR Detection of Drug-Resistant Mycobacterium tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting drug-resistant Mycobacterium tuberculosis (MTB) strains, particularly those resistant to rifampicin (MTB-RIF) and isoniazid (MTB-INH), are slow and unable to accurately differentiate between wild-type and mutant strains in mixed infections, leading to inadequate treatment outcomes.
Innovation Solution
A real-time PCR method using specific primers and hydrolysis probes designed to detect single nucleotide polymorphisms (SNPs) in the rpoB, inhA, and katG genes, allowing for simultaneous detection and differentiation of MTB-RIF and MTB-INH in a single test tube, with probes optimized to detect specific SNPs conferring resistance without cross-reacting with wild-type MTB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If culturing on solid or liquid media is used for MTB and drug resistance detection, then detection reliability is improved, but detection time increases significantly (up to eight weeks)
Solution Approach 1:
The patent replaces the traditional mechanical culturing system with a molecular biology-based PCR detection system. By using polymerase chain reaction to amplify and detect specific DNA sequences associated with drug resistance, the method achieves rapid detection (within hours) while maintaining high reliability, eliminating the need for time-consuming bacterial culturing.
Solution Approach 2:
The patent uses PCR amplification to create multiple copies of the target DNA sequences from the bacterial genome. This copying process allows for sufficient detection signal to be generated from minimal initial sample material, enabling rapid detection without requiring the bacteria to be cultured to visible colonies over weeks.
2Productivity
If commercial nucleic acid tests are used for fast detection, then detection time is reduced, but detection precision deteriorates (cannot detect small percentage of mutant species in mixed infection)
Solution Approach 1:
The patent designs specific probes with high local specificity to target exact DNA sequences associated with drug resistance mutations. By using probes that match only the mutant sequences (such as rpoB mutations for rifampicin resistance), the method can detect even small proportions of resistant bacteria within a mixed population, achieving both speed and sensitivity.
Solution Approach 2:
The patent optimizes the biochemical parameters of the PCR and hybridization reactions to enhance detection sensitivity. By adjusting conditions such as annealing temperature, probe concentration, and cycle parameters, the method achieves the ability to detect minor mutant populations (as low as 1-5% of total bacteria) while maintaining rapid turnaround time.
3Measurement precision
If multiple separate tests are performed to detect different drug resistances, then detection precision for each strain is improved, but device complexity and operation difficulty increase
Solution Approach 1:
The patent combines multiple detection functions into a single multiplex PCR assay. By designing primers and probes that simultaneously target multiple drug resistance genes (such as rpoB for rifampicin resistance, inhA and katG for isoniazid resistance) in one reaction tube, the method achieves comprehensive resistance profiling without requiring separate tests, thereby reducing complexity while maintaining precision.
Solution Approach 2:
The patent creates a universal detection platform that can identify multiple types of drug resistance through a single test system. The assay is designed to detect various mutations across different bacterial genes using a standardized protocol, making the system multi-functional and eliminating the need for multiple specialized tests.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and accurate detection of drug-resistant MTB strains, even in mixed infections, improving treatment efficacy by identifying minor populations of resistant bacteria that previous methods may miss.
Implementation Method 1
performing a hybridizing step comprising contacting the one or more amplification products with a plurality of detectable rpoB probes, a plurality of detectable inhA probes, and a plurality of detectable katG probes
Implementation Method 2
detecting the presence or absence of the one or more amplification products
Data Source
AI summary
Methods for the rapid detection of the presence or absence of Mycobacterium tuberculosis (MTB) resistant to rifampicin (MTB-RIF) and/or MTB resistant to isoniazid (MTB-INH) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the genes for rpoB, inhA, and katG, along with kits are provided that are designed for the detection of MTB-RIF and/or MTB-INH.